Tag Archives: Yi Chen
H.C. Wainwright Sticks to Its Hold Rating for Zynex (ZYXI)
In a report released today, Yi Chen from H.C. Wainwright maintained a Hold rating on Zynex (ZYXI – Research Report), with a price target of $20.00. The company’s shares closed last Monday at $20.26, close to its 52-week high of
Bio-Path Holdings (BPTH) Gets a Buy Rating from H.C. Wainwright
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTH – Research Report), with a price target of $18.00. The company’s shares closed last Friday at $4.75, close to its 52-week low
H.C. Wainwright Sticks to Their Buy Rating for Eyenovia (EYEN)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Eyenovia (EYEN – Research Report) today and set a price target of $6.00. The company’s shares closed last Wednesday at $3.60. According to TipRanks.com, Chen is a 5-star analyst with
H.C. Wainwright Keeps a Buy Rating on Aslan Pharmaceuticals (ASLN)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals (ASLN – Research Report), with a price target of $5.00. The company’s shares closed last Tuesday at $1.95. According to TipRanks.com, Chen is
H.C. Wainwright Thinks Celcuity’s Stock is Going to Recover
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Celcuity (CELC – Research Report), with a price target of $11.00. The company’s shares closed last Thursday at $5.51, close to its 52-week low of
H.C. Wainwright Thinks Stealth Biotherapeutics’ Stock is Going to Recover
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Stealth Biotherapeutics (MITO – Research Report), with a price target of $4.00. The company’s shares closed last Thursday at $1.66, close to its 52-week low
